Rebecca S Kristeleit

25PUBLICATIONS
174CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Apr 08, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno

|Feb 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado

|Jul 22, 2025
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.

Kenneth Sooi, Tuan Zea Tan, Jae-Weon Kim

|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.

Timothy A Yap, Patricia LoRusso, Rowan E Miller

|Apr 10, 2025
Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction.

Gabriel Osborn, Jacobo López-Abente, Rebecca Adams

|Mar 06, 2025
Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.

Chara Stavraka, Jitesh Chauhan, Silvia Crescioli

Pageof 5

Frequent Collaborators

5 joint publications

Iain McNeish

5 joint publications

Susana Banerjee

4 joint publications

Sarah P Blagden

4 joint publications

Sophia N Karagiannis